Imamura, Yoshinori http://orcid.org/0000-0002-5202-531X
Otsui, Kazunori
Mori, Kenta
Kitagawa, Koichi
Okada, Hideaki
Hata, Akito
Hayashi, Hidetoshi
Nose, Taku
Ohata, Shinya
Miyata, Yoshiharu
Funakoshi, Yohei
Toyoda, Masanori
Yakushijin, Kimikazu
Kiyota, Naomi
Matsuoka, Hiroshi
Minami, Hironobu
Funding for this research was provided by:
Training Plan for Oncology Professionals, Japan
Article History
Received: 7 October 2021
Revised: 14 January 2022
Accepted: 14 January 2022
First Online: 25 January 2022
Declarations
:
: Yoshinori Imamura has received speakers’ bureau/honoraria from Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, and Pfizer. Kazunori Otsui has received speakers’ bureau/honoraria from Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, and Pfizer. Akito Hata has received speakers’ bureau/honoraria from Bristol-Myers Squibb, Daiichi-Sankyo, and Pfizer. Hidetoshi Hayashi has received speakers’ bureau/honoraria and research grant support from Bristol-Myers Squibb, Daiichi-Sankyo, and Pfizer. Kimikazu Yakushijin has received speakers’ bureau/honoraria from Pfizer. Kiyota Naomi has received speakers’ bureau/honoraria from Bayer and Bristol-Myers Squibb and research grant support from Bayer, Bristol-Myers Squibb, and Pfizer. Hiroshi Matsuoka has received speakers’ bureau/honoraria from Bristol-Myers Squibb and Pfizer. Hironobu Minami has received speakers’ bureau/honoraria from Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, and Pfizer and research grant support from Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, and Pfizer. The other authors declare that they have no conflict of interest in the submitted work.